PALI Relative Valuation
PALI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PALI is overvalued; if below, it's undervalued.
Historical Valuation
Palisade Bio Inc (PALI) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.38. The fair price of Palisade Bio Inc (PALI) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：1.90
Fair
-10.99
PE
1Y
3Y
5Y
0.00
EV/EBITDA
Palisade Bio Inc. (PALI) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
-9.90
EV/EBIT
Palisade Bio Inc. (PALI) has a current EV/EBIT of -9.90. The 5-year average EV/EBIT is -0.37. The thresholds are as follows: Strongly Undervalued below -3.70, Undervalued between -3.70 and -2.04, Fairly Valued between 1.29 and -2.04, Overvalued between 1.29 and 2.96, and Strongly Overvalued above 2.96. The current Forward EV/EBIT of -9.90 falls within the Strongly Undervalued range.
0.00
PS
Palisade Bio Inc. (PALI) has a current PS of 0.00. The 5-year average PS is 8.47. The thresholds are as follows: Strongly Undervalued below -35.22, Undervalued between -35.22 and -13.37, Fairly Valued between 30.32 and -13.37, Overvalued between 30.32 and 52.16, and Strongly Overvalued above 52.16. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Palisade Bio Inc. (PALI) has a current P/OCF of 0.00. The 5-year average P/OCF is -0.38. The thresholds are as follows: Strongly Undervalued below -1.81, Undervalued between -1.81 and -1.10, Fairly Valued between 0.33 and -1.10, Overvalued between 0.33 and 1.04, and Strongly Overvalued above 1.04. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Palisade Bio Inc. (PALI) has a current P/FCF of 0.00. The 5-year average P/FCF is -0.33. The thresholds are as follows: Strongly Undervalued below -1.29, Undervalued between -1.29 and -0.81, Fairly Valued between 0.15 and -0.81, Overvalued between 0.15 and 0.63, and Strongly Overvalued above 0.63. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Palisade Bio Inc (PALI) has a current Price-to-Book (P/B) ratio of 7.10. Compared to its 3-year average P/B ratio of 0.95 , the current P/B ratio is approximately 644.93% higher. Relative to its 5-year average P/B ratio of -661.41, the current P/B ratio is about -101.07% higher. Palisade Bio Inc (PALI) has a Forward Free Cash Flow (FCF) yield of approximately -2.71%. Compared to its 3-year average FCF yield of -234.81%, the current FCF yield is approximately -98.85% lower. Relative to its 5-year average FCF yield of -188.55% , the current FCF yield is about -98.56% lower.
7.10
P/B
Median3y
0.95
Median5y
-661.41
-2.71
FCF Yield
Median3y
-234.81
Median5y
-188.55
Competitors Valuation Multiple
The average P/S ratio for PALI's competitors is 6.19, providing a benchmark for relative valuation. Palisade Bio Inc Corp (PALI) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of PALI increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of PALI in the past 1 year is driven by Unknown.
People Also Watch
TIRX
Tian Ruixiang Holdings Ltd
0.42USD
5.00%
THAR
Tharimmune Inc
2.91USD
-3.32%
SGBX
Safe & Green Holdings Corp
1.96USD
1.55%
CELZ
Creative Medical Technology Holdings Inc
2.45USD
2.51%
PAPL
Pineapple Financial Inc
2.24USD
56.64%
PW
Power REIT
0.8917USD
2.18%
ALBT
Avalon Globocare Corp
1.25USD
4.17%
CPHI
China Pharma Holdings Inc
1.355USD
0.37%
Frequently Asked Questions
Is Palisade Bio Inc (PALI) currently overvalued or undervalued?
Palisade Bio Inc (PALI) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -1.38. The fair price of Palisade Bio Inc (PALI) is between NaN to NaN according to relative valuation methord.
What is Palisade Bio Inc (PALI) fair value?
PALI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Palisade Bio Inc (PALI) is between NaN to NaN according to relative valuation methord.
How does PALI's valuation metrics compare to the industry average?
The average P/S ratio for PALI's competitors is 6.19, providing a benchmark for relative valuation. Palisade Bio Inc Corp (PALI) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Palisade Bio Inc (PALI) as of Jan 08 2026?
As of Jan 08 2026, Palisade Bio Inc (PALI) has a P/B ratio of 7.10. This indicates that the market values PALI at 7.10 times its book value.
What is the current FCF Yield for Palisade Bio Inc (PALI) as of Jan 08 2026?
As of Jan 08 2026, Palisade Bio Inc (PALI) has a FCF Yield of -2.71%. This means that for every dollar of Palisade Bio Inc’s market capitalization, the company generates -2.71 cents in free cash flow.
What is the current Forward P/E ratio for Palisade Bio Inc (PALI) as of Jan 08 2026?
As of Jan 08 2026, Palisade Bio Inc (PALI) has a Forward P/E ratio of -10.99. This means the market is willing to pay $-10.99 for every dollar of Palisade Bio Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Palisade Bio Inc (PALI) as of Jan 08 2026?
As of Jan 08 2026, Palisade Bio Inc (PALI) has a Forward P/S ratio of 0.00. This means the market is valuing PALI at $0.00 for every dollar of expected revenue over the next 12 months.